Clinical Trial

Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP

Name: Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP — clinical trial record (NCT07552324)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.

Trial Details

NCT Number	NCT07552324
Lead Sponsor	Ruijin Hospital
Conditions	DHL, THL, DLBCL - Diffuse Large B Cell Lymphoma
Enrollment	28 participants
Start Date	2026-05-01
Primary Completion	2027-05-31 (estimated)
Study Completion	2028-05-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-27